Research Analysts Set Expectations for AGIO FY2028 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities research analysts at Zacks Research issued their FY2028 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research note issued to investors on Wednesday, March 4th. Zacks Research analyst Team anticipates that the biopharmaceutical company will post earnings per share of ($3.61) for the year. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share.

Other equities research analysts have also recently issued reports about the stock. Leerink Partners lifted their price objective on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, December 26th. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Bank of America upped their target price on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, December 29th. Finally, JPMorgan Chase & Co. upped their price objective on Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $40.67.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $27.68 on Friday. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The business has a 50-day simple moving average of $28.07 and a 200-day simple moving average of $33.33. The company has a market cap of $1.62 billion, a PE ratio of -3.89 and a beta of 0.89.

Institutional Trading of Agios Pharmaceuticals

A number of large investors have recently made changes to their positions in AGIO. Creative Planning increased its stake in shares of Agios Pharmaceuticals by 2.2% in the third quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock worth $527,000 after buying an additional 280 shares during the last quarter. Assetmark Inc. increased its position in shares of Agios Pharmaceuticals by 37.9% in the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 362 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Agios Pharmaceuticals by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock valued at $4,393,000 after purchasing an additional 512 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Agios Pharmaceuticals by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,834 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 588 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Agios Pharmaceuticals by 1.2% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 55,284 shares of the biopharmaceutical company’s stock valued at $1,839,000 after buying an additional 633 shares during the last quarter.

Insider Activity at Agios Pharmaceuticals

In related news, insider Sarah Gheuens sold 2,932 shares of the business’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the sale, the insider directly owned 64,795 shares in the company, valued at $1,755,296.55. The trade was a 4.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tsveta Milanova sold 2,872 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $27.02, for a total transaction of $77,601.44. Following the completion of the sale, the insider owned 34,793 shares in the company, valued at $940,106.86. This represents a 7.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 33,303 shares of company stock worth $901,977. 4.30% of the stock is currently owned by insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.